Premium
Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia
Author(s) -
Palau Anna,
Mallo Mar,
Palomo Laura,
RodríguezHernández Ines,
Diesch Jeannine,
Campos Diana,
Granada Isabel,
Juncà Jordi,
Drexler Hans G.,
Solé Francesc,
Buschbeck Marcus
Publication year - 2017
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.22430
Subject(s) - myeloid leukemia , myelodysplastic syndromes , loss of heterozygosity , hematology , biology , myeloid , leukemia , cancer research , oncology , medicine , gene , immunology , genetics , bone marrow , allele
Leukemia cell lines have been widely used in the hematology field to unravel mechanistic insights and to test new therapeutic strategies. Myelodysplastic syndromes (MDS) comprise a heterogeneous group of diseases that are characterized by ineffective hematopoiesis and frequent progress to acute myeloid leukemia (AML). A few cell lines have been established from MDS patients after progression to AML but their characterization is incomplete. Here we provide a detailed description of the immunophenotypic profile of the MDS‐derived cell lines SKK‐1, SKM‐1, F‐36P; and MOLM‐13. Specifically, we analyzed a comprehensive panel of markers that are currently applied in the diagnostic routine for myeloid disorders. To provide high‐resolution genetic data comprising copy number alterations and losses of heterozygosity we performed whole genome single nucleotide polymorphism‐based arrays and included the cell line OHN‐GM that harbors the frequent chromosome arm 5q deletion. Furthermore, we assessed the mutational status of 83 disease‐relevant genes. Our results provide a resource to the MDS and AML field that allows researchers to choose the best‐matching cell line for their functional studies. © 2016 Wiley Periodicals, Inc.